Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 20/20 | 0.49 |
| ▸ | FGF2 | P09038 | 1/20 | 0.48 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.48 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5101884 | 0.92 | FGFR1 (0.49) | FGFR1FGF2FGFR4FGFR3 | |
| SCHEMBL5115233 | 0.88 | KDR (0.46) | FGFR1 | |
| SCHEMBL5108338 | 0.85 | FGFR1 (0.49) | FGFR1FGF2FGFR4FGFR3 | |
| SCHEMBL5108231 | 0.84 | BRAF (0.43) | FGFR1FGF2FGFR4FGFR3 | |
| SCHEMBL5108796 | 0.84 | FGFR1 (0.47) | FGFR1FGF2FGFR4FGFR3 | |
| SCHEMBL5115092 | 0.82 | GCK (0.44) | FGFR1FGF2FGFR4FGFR3 | |
| SCHEMBL5102563 | 0.81 | MAOA (0.43) | FGFR1FGF2FGFR4FGFR3 | |
| SCHEMBL13999517 | 0.79 | FGFR1 (0.44) | FGFR1 | |
| SCHEMBL5115905 | 0.79 | KDR (0.39) | FGFR1FGF2FGFR4FGFR3 | |
| SCHEMBL5101352 | 0.78 | FGFR1 (0.42) | FGFR1FGF2FGFR4FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7468380-B2 | Nitrogen-containing aromatic derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-12-23 | — | — | US | disclosed |
| US-7468380-B2 | Nitrogen-containing aromatic derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-12-23 | — | — | US | disclosed |
| US-7468380-B2 | Nitrogen-containing aromatic derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-12-23 | — | — | US | disclosed |
| US-20070004764-A1 | Nitrogen-containing aromatic derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-01-04 | — | — | US | disclosed |
| US-20070004764-A1 | Nitrogen-containing aromatic derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-01-04 | — | — | US | disclosed |
| US-20070004764-A1 | Nitrogen-containing aromatic derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-01-04 | — | — | US | disclosed |
| US-7109219-B2 | Nitrogen-containing aromatic derivatives | EISAI CO., LTD. (JP) | 2006-09-19 | — | — | US | disclosed |
| US-20060004029-A1 | Nitrogen-containing aromatic derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-01-05 | — | — | US | disclosed |
| US-20050187236-A1 | Nitrogen-containing aromatic derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-08-25 | — | — | US | disclosed |
| EP-1522540-A1 | AZAARENE DERIVATIVES | Eisai Co., Ltd. (JP) | 2005-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004029-A1 | Nitrogen-containing aromatic derivatives | NR0B2, NR0B1, NR4A1 | FGFR1 595/4885FGF2 1924/4885FGFR4 1265/4885 |
| US-20050187236-A1 | Nitrogen-containing aromatic derivatives | NR0B2, NR0B1, NR4A1 | FGFR1 595/4885FGF2 1924/4885FGFR4 1265/4885 |
| US-20070004764-A1 | Nitrogen-containing aromatic derivatives | NR0B2, NR0B1, NR4A1 | FGFR1 595/4885FGF2 1924/4885FGFR4 1265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.